Donepezil Hydrochloride
Product Images NDC 69150-415

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 69150-415). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biomes Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Donepezil Hydrochloride Structural Formula (Image 01)

Donepezil Hydrochloride Structural Formula (Image 01)
FDA Label Image

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Image 02)

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Image 02)
FDA Label Image

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Image 03)

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Image 03)
FDA Label Image

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Image 04)

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Image 04)
FDA Label Image

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Image 05)

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Image 05)
FDA Label Image

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Image 06)

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Image 06)
FDA Label Image

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Image 07)

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Image 07)
FDA Label Image

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Image 08)

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Image 08)
This appears to be a partial table or chart with incomplete headers and data. It is not possible to generate a useful description with the given information.*
FDA Label Image

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Image 09)

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Image 09)
Not available.*
FDA Label Image

Figure 9: Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Image 10)

Figure 9: Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Image 10)
FDA Label Image

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Image 11)

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Image 11)
FDA Label Image

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Image 12)

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Image 12)
FDA Label Image

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Image 13)

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Image 13)
FDA Label Image

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Image 14)

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Image 14)
This appears to be medication information regarding two forms of Donepezil HCI, one at 23mg/day and another at 10mg/day. There is also a table showing improved outcomes for patients, though it is difficult to determine what these outcomes are without additional information.*
FDA Label Image

Image Description (Spl Image Label 10mg)

Image Description (Spl Image Label 10mg)
NDC number 6915041603 corresponds to Donepezil, a medication prescribed in tablet form. Each tablet contains active ingredient Donepezil Hydrochloride USP, 10mg. The usual dosage details are enclosed in the package insert. The product is manufactured by BISMES Pharmaceuticals, LLC and comes in a 30 tablet pack. It is recommended to store the medication under controlled room temperature between 20-25°C.*
FDA Label Image

Donepezil Hydrochloride Tablets 23 mg Bottle Label (Spl Image Label 5mg)

Donepezil Hydrochloride Tablets 23 mg Bottle Label (Spl Image Label 5mg)
This is a description of a medication called Donepezil. Each package contains 30 tablets, each containing 5mg of the active ingredient Donepezil Hydrochloride USP. The usual dosage information is contained in the enclosed package insert. The medication is only available through prescription and should be stored at room temperature (20° to 25° C). This particular medication is distributed by Biomes Pharmaceuticals, LLC.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.